Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | DHFR | P00374 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | MMP8 | P22894 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.34 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.34 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4547696 | 0.80 | TDP1 (0.44) | SMN1; SMN2DHFRTSHRTDP1PKM | |
| SCHEMBL4547691 | 0.80 | SMN1; SMN2 (0.44) | SMN1; SMN2DHFRTSHRTDP1PKM | |
| SCHEMBL9176627 | 0.75 | CA1 (0.62) | SMN1; SMN2DHFRTSHRTDP1PKM | |
| SCHEMBL10588480 | 0.73 | L3MBTL1 (0.42) | TSHRTDP1ALDH1A1F2PRSS1 | |
| SCHEMBL4547697 | 0.71 | ALDH1A1 (0.35) | SMN1; SMN2DHFRTSHRTDP1PKM | |
| SCHEMBL4547694 | 0.71 | ALDH1A1 (0.35) | SMN1; SMN2DHFRTSHRTDP1PKM | |
| SCHEMBL13287262 | 0.70 | SMN1; SMN2 (0.44) | SMN1; SMN2DHFRTSHRTDP1PKM | |
| SCHEMBL4547695 | 0.69 | ALDH1A1 (0.36) | SMN1; SMN2DHFRTSHRTDP1PKM | |
| SCHEMBL4547693 | 0.68 | KMT2A (0.42) | SMN1; SMN2DHFRTSHRTDP1PKM | |
| SCHEMBL5777751 | 0.68 | KDM4E (0.51) | SMN1; SMN2MMP1MMP2MMP9MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9045444-B2 | Apoptosis promoters | ABBVIE INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-20140187531-A1 | APOPTOSIS PROMOTERS | ABBVIE INC. (US) | 2014-07-03 | — | — | US | disclosed |
| US-20130190488-A1 | APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2013-07-25 | — | — | US | disclosed |
| US-8354404-B2 | Apoptosis promoters | ABBOTT LABORATORIES (US) | 2013-01-15 | — | — | US | disclosed |
| US-8173811-B2 | Apoptosis promoters | ABBOTT LABORATORIES (US) | 2012-05-08 | — | — | US | disclosed |
| US-8084607-B2 | Apoptosis promoters | ABBOTT LABORATORIES (US) | 2011-12-27 | — | — | US | disclosed |
| US-20110256129-A1 | APOPTOSIS PROMOTERS | ABBOTT LABORATORIES | 2011-10-20 | — | — | US | disclosed |
| US-7973161-B2 | Apoptosis promoters | ABBOTT LABORATORIES (US) | 2011-07-05 | — | — | US | disclosed |
| US-20110144112-A9 | APOPTOSIS PROMOTERS | ABBVIE INC. | 2011-06-16 | — | — | US | disclosed |
| US-20100240715-A1 | Apoptosis promoters | ABBOTT LABORATORIES | 2010-09-23 | — | — | US | disclosed |
| US-7767684-B2 | Apoptosis promoters | ABBOTT LABORATORIES (US) | 2010-08-03 | — | — | US | disclosed |
| US-20100022773-A1 | APOPTOSIS PROMOTERS | ABBVIE INC. | 2010-01-28 | — | — | US | disclosed |
| US-7642260-B2 | N-acylsulfonamide derivatives; BCL-X1 protein inhibitors; anticarcinogenic agents; bladder cancer; for example, N-(4-(4-((4'-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)-propyl)amino)-3-nitrobenzenesulfonamide | ABBOTT LABORATORIES, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-20070072860-A1 | N-acylsulfonamide derivatives; BCL-X1 protein inhibitors; anticarcinogenic agents; bladder cancer; for example, N-(4-(4-((4'-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)-propyl)amino)-3-nitrobenzenesulfonamide | ABBOTT LABORATORIES | 2007-03-29 | — | — | US | disclosed |
| US-20070015787-A1 | Apoptosis promoters | ABBVIE INC. | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144112-A9 | APOPTOSIS PROMOTERS | BAX, BCL2, API5 | SMN1; SMN2 2412/4885DHFR 645/4885TSHR 4124/4885 |
| US-20130190488-A1 | APOPTOSIS PROMOTERS | BAX, BCL2, API5 | SMN1; SMN2 2412/4885DHFR 645/4885TSHR 4124/4885 |
| US-20070015787-A1 | Apoptosis promoters | BAX, BCL2, API5 | SMN1; SMN2 2412/4885DHFR 645/4885TSHR 4124/4885 |
| US-20100022773-A1 | APOPTOSIS PROMOTERS | BAX, BCL2, API5 | SMN1; SMN2 2412/4885DHFR 645/4885TSHR 4124/4885 |
| US-20100240715-A1 | Apoptosis promoters | BAX, BCL2, API5 | SMN1; SMN2 2412/4885DHFR 645/4885TSHR 4124/4885 |
| US-20140187531-A1 | APOPTOSIS PROMOTERS | BAX, BCL2, API5 | SMN1; SMN2 2412/4885DHFR 645/4885TSHR 4124/4885 |
| US-20070072860-A1 | N-acylsulfonamide derivatives; BCL-X1 protein inhibitors; anticarcinogenic agents; bladder cancer; for example, N-(4-(4-((4'-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)-propyl)amino)-3-nitrobenzenesulfonamide | BCL2A1, BAX, BCL2L1 | SMN1; SMN2 2635/4885DHFR 2722/4885TSHR 4739/4885 |
| US-20110256129-A1 | APOPTOSIS PROMOTERS | BAX, BCL2, API5 | SMN1; SMN2 2412/4885DHFR 645/4885TSHR 4124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.